Cargando…

F91. ASSOCIATION BETWEEN SYMPTOM DIMENSIONS AND EXECUTIVE FUNCTION IN SCHIZOPHRENIA

BACKGROUND: Impaired executive function is a core cognitive deficit in schizophrenia and strongly associated with functional outcomes. Understand the relationship between clinical symptoms and executive function may help the clinician to better manage the cognitive impairment and inform prognosis. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franco, Ana Luiza, Ortiz, Bruno Bertolucci, Ferreira, Felipe, Fonseca, Ana Olívia, Berberian, Arthur de Almeida, Rocha, Deyvis, Noto, Cristiano, Bressan, Rodrigo, Gadelha, Ary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887304/ http://dx.doi.org/10.1093/schbul/sby017.622

Ejemplares similares

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes
por: Berberian, Arthur A., et al.
Publicado: (2018)

Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?
por: Berberian, Arthur A., et al.
Publicado: (2016)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey
por: Costardi, Carlos Gustavo, et al.
Publicado: (2022)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

Neuropsychological correlates of remission in chronic schizophrenia subjects: The role of general and task-specific executive processes
por: Rabanea-Souza, Thais, et al.
Publicado: (2016)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls
por: Matsuzaka, Camila T., et al.
Publicado: (2017)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

Executive Functions and Psychopathology Dimensions in Deficit and Non-Deficit Schizophrenia
por: Bielecki, Maksymilian, et al.
Publicado: (2023)

S24. PATHWAYS LINKING ENVIRONMENTAL RISKS, POLYGENIC RISK SCORE TO SCHIZOPHRENIA AND PSYCHOTIC EXPERIENCES IN A BRAZILIAN COHORT OF CHILDREN AND ADOLESCENTS
por: Fonseca, Lais, et al.
Publicado: (2020)

M184. SOCIAL SKILLS TRAINING FOR TREATMENT-RESISTANT SCHIZOPHRENIA WITH PREDOMINANTLY NEGATIVE SYMPTOMS
por: Kayo, Monica, et al.
Publicado: (2020)

O12.8. LOWER FAMILY INCOME PREDICTS PSYCHOTIC EXPERIENCES IN A COMMUNITY SAMPLE OF YOUTHS IN BRAZIL: RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
por: Fonseca, Lais, et al.
Publicado: (2018)

Schizophrenia and COVID-19: risks and recommendations
por: Fonseca, Lais, et al.
Publicado: (2020)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
por: Malinowski, Fernando R., et al.
Publicado: (2019)

S91. OPIOID USE AND SCHIZOPHRENIA: AN UPDATE
Publicado: (2020)

T126. PSYCHOTIC EXPERIENCES AND COMMON MENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE: BIDIRECTIONAL AND TRANSDIAGNOSTIC ASSOCIATIONS IN A LONGITUDINAL COMMUNITY-BASED STUDY
por: Pan, Pedro, et al.
Publicado: (2018)

PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia
por: Ota, Vanessa K., et al.
Publicado: (2014)

S91. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA
por: Choi, Joonho, et al.
Publicado: (2018)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

Executive functions in schizophrenia
por: Sabhesan, S., et al.
Publicado: (2005)

Executive Functioning in Schizophrenia
por: Orellana, Gricel, et al.
Publicado: (2013)

Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families
por: Gadelha, Ary, et al.
Publicado: (2012)

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2019)

Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia
por: Gadelha, A, et al.
Publicado: (2015)

T159. STRUCTURAL BRAIN ABNORMALITIES IN SCHIZOPHRENIA IN ADVERSE ENVIRONMENTS: EXAMINING THE EFFECT OF POVERTY AND VIOLENCE IN SIX LATIN AMERICAN CITIES
por: Crossley, Nicolas, et al.
Publicado: (2020)

GPR91: expanding the frontiers of Krebs cycle intermediates
por: de Castro Fonseca, Matheus, et al.
Publicado: (2016)

What is the Best Latent Structure of Negative Symptoms in Schizophrenia? A Systematic Review
por: Haguiara, Bernardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ue0acdmfmdcpmlq83u5b6a614m